1:37 am Gilead Sciences announces Phase 2 results for two investigational all-oral sofosbuvir-based regimens for the treatment of Chronic Hepatitis C

more

View todays social media effects on GILD

View the latest stocks trending across Twitter. Click to view dashboard

See who Gilead is hiring next, click here to view